A clinical trial to study the effect of the drug INDIRATHI DRAVAGAM in patients having White discharge(Leucorrhea)

Evaluation of INDIRATHI DRAVAGAM for KABAYONI ROGAM(Vulvovaginal candidiasis)-An open clinical study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016540

Enrollment

Registered

2018-12-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B373- Candidiasis of vulva and vagina

Interventions

Intervention1: Kadukkai Vallaraiyin Thani Maanbu: 20 to 40 ml of Indirathi Dravagam is administered twice a day with milk for 48 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Curdy white vaginal discharge Pruritis vulva Dysuria Lowback ache and lower abdominal pain Positive candida albicans Diabetes Mellitus

Exclusion criteria

Exclusion criteria: Sexually transmitted diseases(Syphilis,Gonorrhoea,HIV) Non specific leucorrhoea Pregnancy and lactation Malignancy in uterus and ovary Trichomonas and Gardenella vaginalis

Design outcomes

Primary

Measure	Time frame
Outcome is mainly assessed by Wet mount examination and clinical prognosisTimepoint: 48 days	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Saranyashalini S

Government Siddha Medical College

kannan.menaka@yahoo.com9444669661

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026